The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Improving access to CAR-T: the Significance of FDA REMS removal
Muhammad Bilal Abid, MD, Texas Tech University Health Sciences Center, Lubbock, TX, discusses the removal of the Risk Evaluation and Mitigation Strategy (REMS) program for CAR-T therapy, stating that it will democratize access, homogenize barriers, and broaden access to CAR-T and cell therapy outside of academic centers. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
